12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RSV-F vaccine: Phase II data

Top-line data from a double-blind, placebo-controlled, U.S. Phase II trial in 330 women of child-bearing age showed that 60 and 90 µg doses of intramuscular RSV-F vaccine on days 0 and 28 with and without an aluminum phosphate adjuvant were...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >